Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LLF580 in obese subjects with hypertriglyceridemia
NCT03466203Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2018
- Primary completion
- Nov 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and hypertriglyceridemia comparing LLF580 with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 12 weeks. Started Feb 2018; status: completed.
02
Drugs
efimosfermin
03
Conditions
obesityhypertriglyceridemia
Beyond the preview
Go deeper on NCT03466203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466203.